Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Trial Profile

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tralokinumab (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 08 Aug 2017 Primary endpoint has not been met (Change from Baseline in Percent-Predicted Forced Vital Capacity at Week 52), according to results published in the American Journal of Respiratory and Critical Care Medicine.
    • 08 Aug 2017 Results assessing efficacy of Tralokinumab in Adults with Idiopathic Pulmonary Fibrosis published in the American Journal of Respiratory and Critical Care Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top